Home / Deep Research / COX4I2-Related Pancreatic Insufficiency-Anemia-Hyperostosis Syndrome

COX4I2-Related Pancreatic Insufficiency-Anemia-Hyperostosis Syndrome

COX4I2-Related Pancreatic Insufficiency-Anemia-Hyperostosis Syndrome (EPIDACH) — Deep Research Report

Claude MONDO:0012992 Model: claude-opus-4-8

COX4I2-Related Pancreatic Insufficiency-Anemia-Hyperostosis Syndrome (EPIDACH) — Deep Research Report

Disease: COX4I2-related exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis (EPIDACH); MONDO:0012992 classifies it under mitochondrial complex IV (cytochrome c oxidase) deficiency MONDO: MONDO:0012992  |  OMIM phenotype: 612714  |  Gene: COX4I2 (HGNC:16232; OMIM:607976; chr20q11.21)  |  Inheritance: autosomal recessive

Executive Summary

EPIDACH is an ultra-rare autosomal recessive multisystem disorder caused by a biallelic missense mutation in COX4I2, the gene encoding the lung/acinar-biased, hypoxia-responsive isoform 2 of structural subunit 4 (COX4) of cytochrome c oxidase (mitochondrial respiratory chain Complex IV). Unlike the encephalomyopathic / Leigh-like presentation typical of most nuclear COX-assembly defects, COX4I2 disease presents as a distinctive non-neurological triad: congenital exocrine pancreatic insufficiency (steatorrhea, malabsorption of lipid-soluble vitamins, failure to thrive), dyserythropoietic anemia, and calvarial hyperostosis. The mechanistic hallmark is tissue-biased Complex IV deficiency: COX4I2 is the predominant COX4 isoform in pancreatic acinar cells, so its loss selectively impairs oxidative phosphorylation in tissues that depend on it, while sparing tissues where the ubiquitous COX4I1 isoform predominates.

The primary human literature is exceptionally small and, after this sweep, considered complete. It comprises one primary report:

  1. Shteyer et al., 2009 (PMID:19268275, Am J Hum Genet 84(3):412–7) — the founding and, to date, only primary report. Four patients with congenital exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis were studied after cystic fibrosis, Shwachman-Bodian-Diamond, Pearson, and Johanson-Blizzard syndromes were excluded; homozygosity mapping identified a homozygous COX4I2 mutation. The mutation markedly reduced COX4I2 expression and attenuated its physiologic hypoxia response. (OMIM #612714 describes 5 affected individuals from 2 consanguineous Arab Muslim families and records the variant as c.412G>A, p.Glu138Lys [E138K]; the specific nucleotide change is not named in the cached PubMed abstract, so the YAML cites only what the abstract states and does not assert the E138K detail as snippet-validated evidence.)

A separate ClinVar submission (NM_032609.3(COX4I2):c.1-6C>T, a 5′-UTR/splice-region variant) is annotated to the same condition but is not backed by a distinct primary clinical report and was not used as evidence.

No curative therapy exists; management is supportive — pancreatic enzyme replacement therapy (PERT) for the exocrine pancreatic insufficiency, fat-soluble vitamin supplementation, and transfusion/supportive care for the anemia.

1. Literature Completeness Check (the point of this sweep)

Targeted searches (PubMed/Google Scholar-style queries via WebSearch, plus a fetch of the 2022 Frontiers in Pediatrics review of congenital exocrine pancreatic insufficiency etiologies) were run to find any COX4I2/EPIDACH primary literature published after the 2009 founding report:

  • Queries combined the gene symbol (COX4I2) and the disease acronym/phenotype terms (EPIDACH, "exocrine pancreatic insufficiency", "dyserythropoietic anemia", "calvarial hyperostosis") with case-report / novel-variant / second-family modifiers across 2010–2025.
  • The most authoritative secondary source surfaced, Tóth et al. (2022), Frontiers in Pediatrics — "Congenital etiologies of exocrine pancreatic insufficiency" (10.3389/fped.2022.909925), cites only Shteyer et al. 2009 for COX4I2 disease and explicitly states "To date 4 patients have been described with the disease," confirming no second cohort had been reported as of 2022.

Result: no new primary papers. The sweep surfaced no additional families, no novel pathogenic variants beyond the founder allele, and no new functional studies. The entry's reliance on the single PMID:19268275 citation is therefore appropriate and reflects a complete primary literature, not an under-curated one. This mirrors the situation for sibling ultra-rare nuclear COX-deficiency leaf entries (e.g. PET100, TACO1) where the primary literature is likewise near-exhaustive.

2. Anti-NEC / Named-Entity Confirmation

EPIDACH is a member of the high-NEC-risk class flagged in #3889/#4239 (a gene-numbered/eponymic mitochondrial-deficiency series with a "sanity-check membership" caveat in the issue). The identity anchors were cross-checked:

  • Gene: every search consistently resolved COX4I2 (HGNC:16232, chr20q11) to the EPIDACH phenotype; no competing gene dominated the literature.
  • OMIM: the phenotype maps to OMIM #612714, consistent with MONDO:0012992 (pancreatic insufficiency-anemia-hyperostosis syndrome).
  • Membership caveat: MONDO files MONDO:0012992 under complex IV deficiency, but clinically EPIDACH is a distinct multisystem syndrome rather than a classic encephalomyopathy. Consistent with the PR, the entry conforms_to the complex_iv_assembly_deficiency module on mechanistic grounds (subunit loss → Complex IV biogenesis failure → tissue-biased bioenergetic failure) but the decision to add it to the Mitochondrial_Complex_IV_Deficiency grouping is left to a human maintainer (documented in the entry's notes).

3. Mechanism (as curated in the YAML)

  • COX4I2 subunit loss → failed Complex IV assembly. COX4 is an essential structural subunit of cytochrome c oxidase; COX4I2 is the acinar/hypoxia-responsive isoform. Biallelic loss reduces COX4I2 expression and blunts the hypoxia response, destabilizing holoenzyme assembly in COX4I2-dependent tissues.
  • Impaired terminal electron transfer and ATP synthesis. Reduced Complex IV activity impairs cytochrome-c-to-O₂ electron transfer and oxidative ATP synthesis.
  • Tissue-biased bioenergetic failure. Because acinar pancreas, erythroid lineage, and calvarium rely on COX4I2, the deficit is selectively expressed there, producing the EPIDACH triad while sparing the CNS (in contrast to most nuclear COX defects).

4. Treatment / Management

No disease-modifying therapy. Supportive management curated in the entry:

  • Pancreatic enzyme replacement therapy (PERT) — pharmacotherapy (pancrelipase) for exocrine pancreatic insufficiency and steatorrhea.
  • Fat-soluble vitamin (A/D/E/K) supplementation — dietary intervention for the documented malabsorption / reduced vitamin E.
  • Supportive care — transfusion and general support for the dyserythropoietic anemia.

5. Sources

  • Shteyer E, Saada A, Shaag A, et al. Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene. Am J Hum Genet. 2009;84(3):412–7. PMID:19268275 — PubMed / doi:10.1016/j.ajhg.2009.02.006
  • OMIM #612714 — Exocrine Pancreatic Insufficiency, Dyserythropoietic Anemia, and Calvarial Hyperostosis — omim.org/entry/612714
  • Tóth et al. Congenital etiologies of exocrine pancreatic insufficiency. Front Pediatr. 2022;10:909925 — doi:10.3389/fped.2022.909925 (secondary review; cites only Shteyer 2009 for COX4I2)
  • ClinVar RCV000395757 — NM_032609.3(COX4I2):c.1-6C>T annotated to EPIDACH (no distinct primary clinical report; not used as evidence)